TPD52L1-ROS1 Rearrangement as a new Acquired Resistance...

  • Main
  • 2020 / 3
  • TPD52L1-ROS1 Rearrangement as a new Acquired Resistance...
JTO Clinical and Research Reports 2020 / 3

TPD52L1-ROS1 Rearrangement as a new Acquired Resistance Mechanism to Osimertinib that responds to Crizotinib in combination with Osimertinib in Lung Adenocarcinoma

Xu, Caihua, Li, Dapeng, Duan, Weiming, Tao, Min
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
JTO Clinical and Research Reports
DOI:
10.1016/j.jtocrr.2020.100034
Date:
March, 2020
File:
PDF, 1016 KB
2020
Conversion to is in progress
Conversion to is failed